CURR - CURE Pharma to test sildenafil citrate for erectile dysfunction

The FDA has signed off CURE Pharmaceutical's (CURR) Investigational New Drug application for its CUREfilm Blue, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra) for the treatment of erectile dysfunction.The company is seeking approval of this product via the 505(b)(2) regulatory pathway to expedite the U.S. approval process.The company says that it is confident of starting trials in early 2021.The global erectile dysfunction drug market is projected to reach about $6.6B by 2025, CURE said citing a report by QYR Research.

For further details see:

CURE Pharma to test sildenafil citrate for erectile dysfunction